AcariaHealth is a national comprehensive specialty pharmacy focused on improving care and outcomes for patients living with complex and chronic conditions. Our center of excellence for home infusion and hemophilia specializes in immunoglobulin. We work closely with physician offices to support patients on intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) therapy across various disease states. Our goal is to provide superior support to our providers and unrivaled care to our patients.

For additional pharmacist support, call 866.506.2626 ext. 6080070

Transforming Lives with Compassionate Care





Phone: 866.506.2626 | Fax: 800.696.0607







Product Name	Cutaquig®	HYQVIA®		Gamunex-C®	Xembify®	Gammagard Liquid	Hizentra®	Cuvitru®
Indications	• PI	Recombinant Human Hyaluronidase Human IG infusion (10%) Patients (≥ 16 years) with PI associated with defects in humoral immunity. This includes, but is not limited to, CVID, X-LA, congenital agammaglobulinemia, Wis-kott-Aldrich syndrome, severe combined		Intravenous (IV): CIDP, PI, ITP Subcutaneous (SC): PI	Subcutaneous (SC): primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older	Adult and pediatric patients 2 years and older with PI. Adult patients with Multifocal Motor Neuropathy (MMN)	• PID in pediatric patients 2 years of age and older. CIDP in adults	• PI in adults and children 2+ years old
Contra- indications	Anaphylactic or severe systemic reactions to human IG or any other components of CUTAQUIG such as Polysorbate 80 IgA deficient patients with antibodies against IgA and history of hypersensitivity	 immunodeficiencies, and with CIDP in adults Anaphylactic or severe systemic reactions to human IG IgA deficient patients with antibodies against IgA and history of hypersensitivity Systemic hypersensitivity to hyaluronidase or Recombinant Human Hyaluronidase of HYQVIA 		Anaphylactic or severe systemic reactions to human IG IgA deficient patients with antibodies against IgA and history of hypersensitivity	Anaphylactic or severe systemic reactions to human IG or any other components of Xembify such as Polysorbate 80 IgA deficient patients with antibodies against IgA and history of hypersensitivity	 Anaphylactic or severe systemic reactions to human IG IgA deficient patients with antibodies against IgA and history of hypersensitivity 	Anaphylactic or severe systemic reactions to human IG or components of Hizentra such as polysorbate 80 IgA deficient patients with antibodies against IgA and history of hypersensitivity	Anaphylactic or severe systemic reactions to human IG. IgA deficient patients with antibodies against IgA and history of hypersentivity
IgA Content	· < 600 ug/ml	· 0 ug/ml	· Average 37 ug/ml	Average 46 mcg/ml	· Average IgA: 68+19 µg/ml, average IgM: <4 µg/ml	· 37 mcg/ml	· ≤ 50 mcg/ml (20%)	· 80mcg/ml
Osmolality	· 310-380 mOsmol/kg	• 240-300 mOsmol/kg (physiologic range: 285-295)		• 258 mOsmol/kg	• 280-404 mOSm/kg	• 240-300 mOsm/kg	· 380 mOsm/kg	• 280-292mOsm/kg
Sugar Content	· Maltose	· Glycine		· Glycine	• Glycine and Polysorbate 80	· Glycine	· L-proline	· Glycine
Sodium Content	· <30 mg/ml	• No sodium		Trace amounts	· Trace amounts	· No sodium	· Trace amounts	· No sodium
pH of Product	· 5-5.5	· 4.6-5.1		· 4.0-4.5	· 4.1-4.8	· 4.6-5.1	· 4.6-5.2	· 4.6-5.1
Half Life	• 49.3 days	• Mean: 59.3 days (SD: 36.1)		Approximately 35 days	· N/A	· 35 days	· N/A	105 (71-119) days dependent on disease state, immune system and patient age
Viral Safety Process	 Cold ethanol fractionation followed by ultrafiltration and chromatography Organic S/D mixture composed of tri-n-butyl phosphate (TNBP) and octoxynol Cold ethanol fractionation, S/D treatment and pH 4 treatment 	• S/D treatment, 35 nm filtration, low pH incubation		Caprylate Incubation, Depth Filtration, Column Chromatography, Low pH Incubation	Cold ethanol fractionation, caprylate precipitation and filtration, anion-exchange chromatography	• S/D treatment, 35 nm filtration, low pH incubation	• ph 4.0 incubation, 20nm virus filtration, depth filtration, TSE validation and removal	• S/D treatment, nano-filtration, low PH incubation
Route of Administration	· Subcutaneous (SC)	· Subcutaneous (SC)		Intravenous (IV): CIDP, PI, ITP Subcutaneous (SC): PI	· Subcutaneous (SC)	Intravenous (IV) Subcutaneous (SC): PI	· Subcutaneous (SC)	Subcutaneous (SC)
Formulation & Concentration	· 16.5%	· 10% Liquid		• 10% Liquid	• 20% Liquid	• 10% Liquid	· 20% Liquid	· 20% Liquid
Storage Requirements	 Refrigerator temperature 2°-8°C (36°-46°F) 6 months at room temperature anytime during the 36-month shelf life 	 Refrigerator temperature 2°-8°C (36°-46°F). Do not freeze. 3 months at room temperature during the first 24 months from date of manufacture: 25°C (77°F) 		Refrigerator temperature 2°-8°C (36°-46°F) 6 months at room temperature anytime during the 36-month shelf life	 Refrigerator temperature 2°-8°C (36°-46°F). Following refrigerated storage, use product immediately or discard. 6 months at room temperature anytime during the 36-month shelf life 	 Refrigerator temperature 2°-8°C (36°-46°F). Do not freeze. 24 months at room temperature anytime during the 36-month shelf life. 	Store at room temperature. Does not require refrigeration.	• Refrigerator temperature 2°-8°C (36°-46°F) up to 36 months from the date of manufacture
Shelf Life from Date of Manufacture	· 36 months	· 36 months		· 36 months	· 36 months	· 36 months	· 30 months	· 36 months
How Supplied	· Vial	• Dual vial unit of two single use vials		· Vial	· Vial	· Vial	· Single use, tamper evident vial	· Vial
Available Sizes	· 1 gm, 1.65 gm, 2 gm, 3.3 gm, 4 gm, 8gm	• 1.25 ml, 2.5 ml, 5 ml, 10 ml, 15 ml	• 2.5 gm, 5 gm, 10 gm, 20 gm, 30 gm	· 1 gm, 2.5 gm, 5 gm, 10 gm, 20 gm, 40 gm	∙1 gm, 2 gm, 4 gm, 10 gm	• 1 gm, 2.5 gm, 5 gm, 10 gm, 20 gm, 30 gm	• 1gm, 2gm, 4gm, 10gm pre-filled syringes	• 1gm, 2gm, 4gm, 8gm & 10gm

DISCLAIMER: The information provided herein is a summary of available information only. This summary has been compiled by AcariaHealth and does not represent a clinical comparison conducted by any of the manufacturers reference on any of these pages. It is to be used as a general reference tool only and is not intended for use as a guideline for clinical evaluations. The possibility of error (typographical or otherwise) exists in this summary. AcariaHealth expressly disclaims any and all warranties and liability arising out of or related to this information. Rates: Infuse following manufacturer's recommended guidelines